Unknown OBSERVATIONAL NCT01594541

A Retrospective Analysis of Cerefolin NAC® in Cognitively Impaired Patients

Hyperhomocysteinemia in a Mild Cognitive Impairment and Dementia Population: the Effect of Treatment With Cerefolin NAC® in a Naturalistic Community-based Dementia Practice

Sponsor: Clionsky Neuro Systems Inc.

Conditions Mild Cognitive Impairment

Updated 6 times since 2017 Last updated: Mar 21, 2014 Started: Jan 31, 2013 Primary completion: Aug 31, 2013 Completion: Apr 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01594541, this observational or N/A phase trial focuses on Mild Cognitive Impairment and remains ongoing. Sponsored by Clionsky Neuro Systems Inc., it has been updated 6 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status
Jun 2018 — Jan 2021 [monthly]

Unknown Status
Apr 2018 — Jun 2018 [monthly]

Unknown Status

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Unknown Status NA

First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clionsky Neuro Systems Inc.
Pamlab, Inc.

Data source: Pamlab, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Springfield, United States